Evidence map›Paper›PMID 29982244›Full record

ArticlePathobiology : journal of immunopathology, molecular and cellular biology2019

Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.

Konnie M Hebeda, Alexandar Tzankov, Ludmila Boudova, Leonie Saft, Rob P Hasserjian, Mirthe de Boer, Falko Fend, Attilio Orazi, Roos Leguit

Open access · hybridAbstract read
In one paragraph

Article in Pathobiology : journal of immunopathology, molecular and cellular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. [Differential diagnosis of reactive cytopenias].Pathologie (Heidelberg, Germany) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 6 countries.

Konnie M HebedaDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlandskonnie.hebeda@radboudumc.nl.
Alexandar TzankovInstitute of Pathology, University Hospital Basel, Basel, Switzerland.
Ludmila BoudovaDepartment of Pathology, Charles University Hospital, Pilsen, Czech Republic.
Leonie SaftDepartment of Pathology and Cytology, Karolinska University Hospital and Institute, Stockholm, Sweden.
Rob P HasserjianDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Mirthe de BoerDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Falko FendDepartment of Pathology, University of Tuebingen, Tuebingen, Germany.
Attilio OraziDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.
Roos LeguitDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
University Medical Center Utrecht · NLCharles University · CZCornell University · USKarolinska University Hospital · SEMassachusetts General Hospital · USRadboud University Nijmegen · NLUniversity Hospital of Basel · CHUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 13th workshop of the European Bone Marrow Working Group in Utrecht, The Netherlands, was devoted to studying myelodysplastic syndromes (MDS) and their boundaries. The panel received 44 cases submitted to the 3 invited categories, which included: reactive cytopenias with dysplasia, idiopathic cytopenia of undetermined significance, clonal haematopoiesis of indeterminate potential, idiopathic dysplasia of uncertain significance and overt MDS. For this summary, we have selected 17 cases that highlight difficulties in separating true MDS from other causes of cytopenia and the intricate relationship between clonal haematopoiesis and true MDS. In addition, cases of overt MDS with challenging features were also selected. All cases were stained for p53 expression. Using instructive submitted cases we discuss the following: (1) cytopenia with clonal haematopoiesis not fulfilling MDS criteria, (2) cytopenia and/or dysplasia with germline mutations and/or familial history suggesting an underlying gene defect, (3) MDS based on a recurrent chromosomal abnormality and (4) overt MDS with diagnostic difficulties due to concurrent treatment or disease. The lively discussion in the open forum of the workshop illustrated the need for better integrative understanding of the evolution of acquired genetic abnormalities in haematopoiesis, and the challenge of diagnosing true MDS in cytopenic patients with genetic abnormalities, either germline or acquired.

Indexed as

Chromosome AberrationsAdolescentAdultAgedAged, 80 and overBone MarrowEducationFemaleGenetic TestingHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMyelodysplastic SyndromesSequence Analysis, DNABone marrowClassificationCytopeniaMyelodysplastic syndromeNext-generation sequencingWorkshop

Identifiers

PMID29982244
PMCPMC6482987
OpenAlexW2854106072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.